Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active SLE (LOTUS)
NCT03517722Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Ustekinumab with Placebo (2 arms). Primary endpoint: Systemic Lupus Erythematosus Responder Index-4 Composite Response at 52 weeks. Started Apr 2018; status: terminated.
02
Drugs
ustekinumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03517722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517722.